Gilead Sciences (GILD) Change in Taxes (2009 - 2026)
Gilead Sciences' (GILD) quarterly Change in Taxes came in at $171.0 million in Q2 2026, up 113.15% on a YoY basis from $80.2 million in Q2 2025, and up 689.66% quarter-over-quarter from -$29.0 million in Q1 2026.
Analysis
Gilead Sciences (GILD) Change in Taxes (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Change in Taxes for 18 consecutive years, with $171.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Taxes rose 113.15% year-over-year to $171.0 million; the trailing twelve-month figure through Jun 2026 stood at -$114.0 million (up 90.54% YoY), and the FY2025 full-year result was -$2.1 billion, down 187.98% from the prior year.
- Change in Taxes climbed to $171.0 million in Q2 2026 per GILD's latest filing, from -$29.0 million in the prior quarter.
- Across five years, Change in Taxes topped out at $536.0 million in Q4 2024 and bottomed at -$1.3 billion in Q2 2025.
- Historically, Change in Taxes has averaged -$268.3 million across 5 years, with a median of -$128.0 million in 2025.
- The widest YoY moves for Change in Taxes: up 176.79% in 2024, down 4082.14% in 2024.
- Over 5 years, Change in Taxes stood at $119.0 million in 2022, then plunged by 686.55% to -$698.0 million in 2023, then surged by 176.79% to $536.0 million in 2024, then sank by 125.0% to -$134.0 million in 2025, then surged by 227.61% to $171.0 million in 2026.
- According to Business Quant data, Change in Taxes over the past three periods registered $171.0 million, -$29.0 million, and -$134.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | -131.00 Mn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 171.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 13.80 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -10.18 Mn |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 171.00 Mn |
| Mar 31, 2026 | -29.00 Mn |
| Dec 31, 2025 | -134.00 Mn |
| Sep 30, 2025 | -122.00 Mn |
| Jun 30, 2025 | -1.30 Bn |
| Mar 31, 2025 | -552.00 Mn |
| Dec 31, 2024 | 536.00 Mn |
| Sep 30, 2024 | 111.00 Mn |
| Jun 30, 2024 | -1.17 Bn |
| Mar 31, 2024 | -208.00 Mn |
| Dec 31, 2023 | -698.00 Mn |
| Sep 30, 2023 | -881.00 Mn |
| Jun 30, 2023 | -28.00 Mn |
| Mar 31, 2023 | -161.00 Mn |
| Dec 31, 2022 | 119.00 Mn |
| Sep 30, 2022 | 108.00 Mn |
| Jun 30, 2022 | -479.00 Mn |
| Mar 31, 2022 | -112.00 Mn |
| Dec 31, 2021 | 102.00 Mn |
| Sep 30, 2021 | 72.00 Mn |